These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3092310)

  • 1. Half-life and clearance of pH 6.8 and pH 4.25 immunoglobulin G intravenous preparations in patients with primary disorders of humoral immunity.
    Schiff RI
    Rev Infect Dis; 1986; 8 Suppl 4():S449-56. PubMed ID: 3092310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogen-specific IgG antibody levels in immunodeficient patients receiving immunoglobulin replacement do not provide additional benefit to therapeutic management over total serum IgG.
    Chua I; Lagos M; Charalambous BM; Workman S; Chee R; Grimbacher B
    J Allergy Clin Immunol; 2011 Jun; 127(6):1410-1. PubMed ID: 21376379
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and toxicity of a new serum immunoglobulin G intravenous preparation, IGIV pH 4.25.
    Pirofsky B
    Rev Infect Dis; 1986; 8 Suppl 4():S457-63. PubMed ID: 3092311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin.
    Mankarious S; Lee M; Fischer S; Pyun KH; Ochs HD; Oxelius VA; Wedgwood RJ
    J Lab Clin Med; 1988 Nov; 112(5):634-40. PubMed ID: 3183495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of a new chemically modified intravenous IgG preparation in severe primary humoral immunodeficiency: clinical efficacy and attempts to individualize dosage.
    Schiff RI; Rudd C; Johnson R; Buckley RH
    Clin Immunol Immunopathol; 1984 Apr; 31(1):13-23. PubMed ID: 6421523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulatory role of intravenous gammaglobulin (IgIV) on the in vitro antibody response to a pneumococcal polysaccharide antigen.
    Leiva LE; Monjure H; Sorensen RU
    J Clin Immunol; 2015 Feb; 35(2):206-12. PubMed ID: 25504423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in the half-life and clearance of IgG during therapy with intravenous gamma-globulin in 16 patients with severe primary humoral immunodeficiency.
    Schiff RI; Rudd C
    J Clin Immunol; 1986 May; 6(3):256-64. PubMed ID: 2424931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations.
    Mikolajczyk MG; Concepcion NF; Wang T; Frazier D; Golding B; Frasch CE; Scott DE
    Clin Diagn Lab Immunol; 2004 Nov; 11(6):1158-64. PubMed ID: 15539522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring of two intravenous immunoglobulin. Preparations for immunoglobulin G subclasses and specific antibodies to bacterial surface antigens and relation with their levels in treated immunodeficient patients.
    Lamari F; Karamanos NK; Papadopoulou-Alataki E; Kanakoudi-Tsakalidou F; Dimitracopoulos G; Anastassiou ED
    J Pharm Biomed Anal; 2000 Jul; 22(6):1029-36. PubMed ID: 10857572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective evaluation of Streptococcus pneumoniae serum antibodies in patients with primary immunodeficiency on regular intravenous immunoglobulin treatment.
    Simão-Gurge RM; Costa-Carvalho BT; Nobre FA; Gonzalez IG; de Moraes-Pinto MI
    Allergol Immunopathol (Madr); 2017; 45(1):55-62. PubMed ID: 27480789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%).
    Ballow M; Berger M; Bonilla FA; Buckley RH; Cunningham-Rundles CH; Fireman P; Kaliner M; Ochs HD; Skoda-Smith S; Sweetser MT; Taki H; Lathia C
    Vox Sang; 2003 Apr; 84(3):202-10. PubMed ID: 12670369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pneumococcal antibody levels in children with PID receiving immunoglobulin.
    Tuerlinckx D; Florkin B; Ferster A; De Schutter I; Chantrain C; Haerynck F; Philippet P; Strengers P; Laub R
    Pediatrics; 2014 Jan; 133(1):e154-62. PubMed ID: 24366995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualizing the dose of intravenous immune serum globulin for therapy of patients with primary humoral immunodeficiency.
    Schiff RI
    Vox Sang; 1985; 49 Suppl 1():15-24. PubMed ID: 2416124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency.
    Wasserman RL; Church JA; Peter HH; Sleasman JW; Melamed I; Stein MR; Bichler J;
    Eur J Pharm Sci; 2009 Jun; 37(3-4):272-8. PubMed ID: 19491015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes of tetanus specific IgG, IgM and IgG subclasses after DPT vaccination.
    Kim JS; Kim SJ; Shin KJ; Hwang PH; Cho SC
    Yonsei Med J; 1989; 30(2):158-63. PubMed ID: 2678764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgG antibody reactive with five serotypes of Streptococcus pneumoniae in commercial intravenous immunoglobulin preparations.
    Hamill RJ; Musher DM; Groover JE; Zavell PJ; Watson DA
    J Infect Dis; 1992 Jul; 166(1):38-42. PubMed ID: 1607706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of intravenous gamma globulin in multiple myeloma.
    Gordon DS; Hearn EB; Spira TJ; Reimer CB; Phillips DJ; Schable C
    Am J Med; 1984 Mar; 76(3A):111-6. PubMed ID: 6424442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of total immunoglobulin G and immunoglobulin G subclasses in patients undergoing replacement therapy for primary immunodeficiency syndromes.
    Alyanakian MA; Bernatowska E; Scherrmann JM; Aucouturier P; Poplavsky JL
    Vox Sang; 2003 Apr; 84(3):188-92. PubMed ID: 12670367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three generations of immunoglobulin G preparations for clinical use.
    McCue JP; Hein RH; Tenold R
    Rev Infect Dis; 1986; 8 Suppl 4():S374-81. PubMed ID: 3092303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective and opsonic activities of a native, pH 4.25 intravenous immunoglobulin G preparation against common bacterial pathogens.
    Hill HR; Bathras JM
    Rev Infect Dis; 1986; 8 Suppl 4():S396-400. PubMed ID: 3092306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.